Nivolumab plus ipilimumab for untreated unresectable or metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency. NICE technology appraisal guidance 1065
National Institute for Health and Care Excellence (NICE)
Record ID 32018014251
English
Details
Project Status:
Completed
URL for project:
https://www.nice.org.uk/guidance/ta1065
Year Published:
2025
URL for published report:
https://www.nice.org.uk/guidance/ta1065
English language abstract:
An English language summary is available
Publication Type:
Full HTA
Country:
England
MeSH Terms
- Colorectal Neoplasms
- Nivolumab
- Ipilimumab
- Antineoplastic Combined Chemotherapy Protocols
- Antineoplastic Agents, Immunological
Contact
Organisation Name:
National Institute for Health and Care Excellence
Contact Address:
Level 1A, City Tower, Piccadilly Plaza, Manchester, M1 4BT
Contact Name:
nice@nice.nhs.uk
Contact Email:
nice@nice.nhs.uk
Copyright:
National Institute for Health and Care Excellence (NICE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.